Three existing AML treatments: cytarabine (a cytotoxic agent), venetoclax (a BCL-2 inhibitor), and chidamide (a histone deacetylase inhibitor) were examined on affecting the inflammatory phenotype of BMSCs. The gene discussed is BCL2; the disease is acute myeloid leukemia.